Published in Infect Immun on October 01, 2002
Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science (2014) 2.99
Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma. Nat Med (2008) 2.25
Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines (2007) 1.50
Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins. Expert Rev Vaccines (2007) 1.17
Cholera toxin, E. coli heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer's patches. Mucosal Immunol (2008) 1.08
HIV-1-suppressive factors are secreted by CD4+ T cells during primary immune responses. Proc Natl Acad Sci U S A (2003) 1.03
Signaling of c-kit in dendritic cells influences adaptive immunity. Ann N Y Acad Sci (2010) 1.00
Calcium signaling through phospholipase C activates dendritic cells to mature and is necessary for the activation and maturation of dendritic cells induced by diverse agonists. Clin Diagn Lab Immunol (2004) 0.95
Anthrax edema toxin induces maturation of dendritic cells and enhances chemotaxis towards macrophage inflammatory protein 3beta. Infect Immun (2009) 0.95
The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens. Infect Immun (2012) 0.93
Cholera toxin indirectly activates human monocyte-derived dendritic cells in vitro through the production of soluble factors, including prostaglandin E(2) and nitric oxide. Clin Vaccine Immunol (2006) 0.89
Self-protection of individual CD4+ T cells against R5 HIV-1 infection by the synthesis of anti-viral CCR5 ligands. PLoS One (2008) 0.86
Cholera toxin and Escherichia coli heat-labile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytes. Infect Immun (2009) 0.86
Dietary resveratrol prevents the development of food allergy in mice. PLoS One (2012) 0.86
Pasteurella multocida toxin activates human monocyte-derived and murine bone marrow-derived dendritic cells in vitro but suppresses antibody production in vivo. Infect Immun (2005) 0.85
An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants. Infect Immun (2003) 0.83
Regulation of Toll-like receptor 4-mediated immune responses through Pasteurella multocida toxin-induced G protein signalling. Cell Commun Signal (2012) 0.83
Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun. Clin Vaccine Immunol (2011) 0.83
A-kinase anchoring in dendritic cells is required for antigen presentation. PLoS One (2009) 0.82
Crosstalk between PKA and Epac regulates the phenotypic maturation and function of human dendritic cells. J Immunol (2010) 0.80
Signaling cascades of Pasteurella multocida toxin in immune evasion. Toxins (Basel) (2013) 0.79
Escherichia coli heat-labile detoxified enterotoxin modulates dendritic cell function and attenuates allergic airway inflammation. PLoS One (2014) 0.78
Cholera toxin directly enhances IL-17A production from human CD4+ T cells. J Immunol (2013) 0.78
Toxins-useful biochemical tools for leukocyte research. Toxins (Basel) (2010) 0.78
Parenteral Adjuvant Effects of an Enterotoxigenic Escherichia coli Natural Heat-Labile Toxin Variant. Front Immunol (2014) 0.76
Induction of Dendritic Cell Maturation and Activation by a Potential Adjuvant, 2-Hydroxypropyl-β-Cyclodextrin. Front Immunol (2016) 0.75
The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responses. Hum Vaccin Immunother (2015) 0.75
Mechanism of adenylate cyclase activation by cholera toxin: inhibition of GTP hydrolysis at the regulatory site. Proc Natl Acad Sci U S A (1977) 4.63
Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology (1986) 3.28
Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun (1995) 3.22
Cholera toxin: interaction of subunits with ganglioside GM1. Science (1974) 3.11
Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol (1995) 2.87
Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci U S A (1995) 2.63
Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells. Biochemistry (1997) 2.59
Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb. Infect Immun (1988) 2.32
Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur J Immunol (2000) 1.85
Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis (1996) 1.68
Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology (1992) 1.68
Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med (1997) 1.61
Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression. J Exp Med (1999) 1.58
Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3',5'-cyclic phosphorothioates. J Biol Chem (1990) 1.57
The mechanism of cholera toxin adjuvanticity. Res Immunol (1998) 1.51
Long-term cholera antitoxin memory in the gut can be triggered to antibody formation associated with protection within hours of an oral challenge immunization. Scand J Immunol (1987) 1.45
Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine (1998) 1.35
Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin. Vaccine (1994) 1.32
Modulating dendritic cells to optimize mucosal immunization protocols. J Immunol (1999) 1.19
Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity. J Immunol (2000) 1.16
Structural basis for the differential toxicity of cholera toxin and Escherichia coli heat-labile enterotoxin. Construction of hybrid toxins identifies the A2-domain as the determinant of differential toxicity. J Biol Chem (1999) 1.11
Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit. Immunology (1998) 1.11
Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB. Vaccine (1989) 1.05
Size and structure of the cholera toxin molecule and its subunits. J Infect Dis (1976) 1.04
Genetically manipulated bacterial toxin as a new generation mucosal adjuvant. Scand J Immunol (2001) 1.00
Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue. Infect Immun (1998) 0.98
Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis. Immunology (1998) 0.97
Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit. Vaccine (1998) 0.93
Cholera toxin B pretreatment of macrophages and monocytes diminishes their proinflammatory responsiveness to lipopolysaccharide. J Immunol (2002) 0.91
Induction of dendritic cell maturation and modulation of dendritic cell-induced immune responses by prostaglandins. Arch Dermatol Res (2000) 0.87
Enterotoxin adjuvants have direct effects on T cells and antigen-presenting cells that result in either interleukin-4-dependent or -independent immune responses. J Infect Dis (2000) 0.85
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 2.74
Exposure to hepatitis C virus induces cellular immune responses without detectable viremia or seroconversion. Am J Trop Med Hyg (2005) 1.56
Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proc Natl Acad Sci U S A (2004) 1.55
Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci U S A (2007) 1.53
Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci U S A (2009) 1.41
Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci U S A (2012) 1.36
Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion. J Virol (2002) 1.30
Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway. J Leukoc Biol (2002) 1.17
HIV-1 transgenic rats develop T cell abnormalities. Virology (2004) 1.14
The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. Cancer Res (2010) 1.12
Role of Fc-mediated antibody function in protective immunity against HIV-1. Immunology (2014) 1.09
An imprinted locus epistatically influences Nstr1 and Nstr2 to control resistance to nerve sheath tumors in a neurofibromatosis type 1 mouse model. Cancer Res (2006) 1.08
Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors. Adv Pharmacol (2007) 1.05
HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proc Natl Acad Sci U S A (2002) 1.04
HIV-1-suppressive factors are secreted by CD4+ T cells during primary immune responses. Proc Natl Acad Sci U S A (2003) 1.03
Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner. Mol Cancer Ther (2010) 1.01
Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. J Transl Med (2005) 0.98
Antigenic properties of the HIV envelope on virions in solution. J Virol (2013) 0.97
Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. J Infect Dis (2002) 0.96
Calcium signaling through phospholipase C activates dendritic cells to mature and is necessary for the activation and maturation of dendritic cells induced by diverse agonists. Clin Diagn Lab Immunol (2004) 0.95
Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies. Neurogenetics (2007) 0.92
Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC Bioinformatics (2008) 0.92
Strong hepatitis C virus (HCV)-specific cell-mediated immune responses in the absence of viremia or antibodies among uninfected siblings of HCV chronically infected children. J Infect Dis (2011) 0.91
Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. J Virol (2012) 0.90
Antibody-based inhibitors of HIV infection. Expert Opin Biol Ther (2006) 0.90
Cholera toxin indirectly activates human monocyte-derived dendritic cells in vitro through the production of soluble factors, including prostaglandin E(2) and nitric oxide. Clin Vaccine Immunol (2006) 0.89
Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine (2002) 0.89
A portable high-intensity focused ultrasound device for noninvasive venous ablation. J Vasc Surg (2010) 0.88
Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J Acquir Immune Defic Syndr (2011) 0.88
Hepatitis C virus-specific cell-mediated immune responses in children born to mothers infected with hepatitis C virus. J Pediatr (2012) 0.87
T cells are depleted in HCV-Induced hepatocellular carcinoma patients: possible role of apoptosis and p53. Egypt J Immunol (2006) 0.86
Self-protection of individual CD4+ T cells against R5 HIV-1 infection by the synthesis of anti-viral CCR5 ligands. PLoS One (2008) 0.86
Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies. Neuro Oncol (2011) 0.86
Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins. J Virol (2011) 0.86
Pasteurella multocida toxin activates human monocyte-derived and murine bone marrow-derived dendritic cells in vitro but suppresses antibody production in vivo. Infect Immun (2005) 0.85
Role of HIV-1 Envelope Glycoproteins Conformation and Accessory Proteins on ADCC Responses. Curr HIV Res (2016) 0.84
Recall antigen activation induces prompt release of CCR5 ligands from PBMC: implication in memory responses and immunization. Int Immunol (2004) 0.84
Cost-effective broad-band electrical impedance spectroscopy measurement circuit and signal analysis for piezo-materials and ultrasound transducers. Meas Sci Technol (2008) 0.83
Molecular immune signatures of HIV-1 vaccines in human PBMCs. FEBS Lett (2009) 0.83
Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun. Clin Vaccine Immunol (2011) 0.83
Conserved structures exposed in HIV-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and potential immunogens. Biochemistry (2002) 0.83
An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants. Infect Immun (2003) 0.83
Schistosomiasis does not affect the outcome of HCV infection in genotype 4-infected patients. Am J Trop Med Hyg (2014) 0.81
Challenges of antibody-mediated protection against HIV-1. Expert Rev Vaccines (2010) 0.81
Synthesis, conformation, and immunogenicity of monosaccharide-centered multivalent HIV-1 gp41 peptides containing the sequence of DP178. Bioorg Med Chem (2004) 0.81
Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma. J Virol (2012) 0.81
Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein. Bioconjug Chem (2004) 0.80
Synthesis and anti-HIV activity of trivalent CD4-mimetic miniproteins. Bioorg Med Chem (2007) 0.80
Introducing infectious agents and cancer. Infect Agent Cancer (2006) 0.80
Protective role of humoral immune responses during an outbreak of hepatitis E in Egypt. Trans R Soc Trop Med Hyg (2012) 0.79
Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians. Hepatol Int (2015) 0.78
Acoustically enhanced Evans blue dye perfusion in neurological tissues. J Acoust Soc Am (2008) 0.78
Ultrasonic modeling and hydrophone measurements of dual divergent transducers for wearable therapeutic ultrasound device. Conf Proc IEEE Eng Med Biol Soc (2014) 0.77
Honing a harder-hitting hammerhead improves broadly neutralizing antibody breadth and potency. J Clin Invest (2015) 0.76
Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment. Curr HIV Res (2016) 0.76
Prevalence of methicillin resistant Staphylococcus aureus among Egyptian patients after surgical interventions. Surg Infect (Larchmt) (2014) 0.76
Elevated suppressor of cytokine signaling-1 (SOCS-1): a mechanism for dysregulated osteoclastogenesis in HIV transgenic rats. Pathog Dis (2014) 0.76
Capturing and characterizing immune cells from breast tumor microenvironment: an innovative surgical approach. Ann Surg Oncol (2010) 0.76
Allosteric induction of the CD4-bound conformation of HIV-1 Gp120. Retrovirology (2013) 0.76
Neutralization of HIV by antibodies. Methods Mol Biol (2009) 0.76
Increased quinolone resistance among typhoid Salmonella isolated from Egyptian patients. J Infect Dev Ctries (2014) 0.75
Time-reversal Techniques in Ultrasound-assisted Convection-enhanced Drug Delivery to the Brain: Technology Development and In Vivo Evaluation. Proc Meet Acoust (2011) 0.75
Human Factors Engineering and testing for a wearable, long duration ultrasound system self-applied by an end user. Conf Proc IEEE Eng Med Biol Soc (2014) 0.75
Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments. J Hum Virol (2002) 0.75
Association of Interleukin-27 rs 153109 Single Nucleotide Polymorphism with Spontaneous Resolution of Hepatitis C Virus - Genotype 4a Infection in Egyptian Patients. Asian Pac J Cancer Prev (2016) 0.75
[Identification of Env-specific monoclonal antibodies from Chinese HIV-1 infected person by B cell activation and RT-PCR cloning]. Bing Du Xue Bao (2012) 0.75